USPTO Examiner SASAN ARADHANA - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19004480IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOFDecember 2024June 2025Allow610NoNo
18889070MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024January 2025Allow400NoNo
18889023MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024December 2024Allow300YesNo
18889055MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2024February 2025Allow500NoNo
18760757MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJuly 2024June 2025Abandon1110NoNo
18758699MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024December 2024Allow610NoNo
18759320MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024February 2025Allow710YesNo
18759364MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024December 2024Allow610NoNo
18758081MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJune 2024October 2024Allow410YesNo
18643773MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSApril 2024August 2024Allow410NoNo
18441901METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUGFebruary 2024August 2025Allow1810NoNo
18539960MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023August 2024Allow810NoNo
18539946MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023August 2024Allow810NoNo
18537332MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023August 2024Allow810NoNo
18537318MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023August 2024Allow810NoNo
18537342MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023June 2024Allow610NoNo
18531095MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023August 2024Allow810NoNo
18531056MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2023June 2024Allow610YesNo
18520348PREPARATION OF SOLID DOSAGE FORMS COMPRISING ANTIBODIES BY SOLUTIONS/SUSPENSION LAYERINGNovember 2023February 2026Allow2720NoNo
18562898AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIANovember 2023March 2026Allow2811NoNo
18388699MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSNovember 2023July 2024Allow820NoNo
18472901MOLECULAR ENTRAPMENT VIA HOMOPOLYMER SELF-ASSEMBLYSeptember 2023July 2025Allow2210NoNo
18368403MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSSeptember 2023July 2024Allow1020NoNo
18241799MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USESeptember 2023March 2026Abandon3011NoNo
18231581MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSAugust 2023November 2023Allow310YesNo
18212233ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOFJune 2023December 2023Allow620YesNo
18144220NOVEL ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOFMay 2023November 2023Abandon710NoNo
18141610Solid Oral Sulfate Salt Formulations For Cleaning A Colon And Methods of Using SameMay 2023February 2026Allow3420NoNo
18134050COMPOSITION FOR IMPROVING EYESIGHTApril 2023November 2025Allow3210NoNo
18120231MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSMarch 2023April 2025Abandon2510NoNo
18119477EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEMarch 2023June 2025Abandon2710NoNo
18179283EMOLLIENT TOPICAL DISINFECTANTSMarch 2023April 2025Abandon2501NoNo
18022372COMPOSITIONS OF GINSENOSIDE RG3 AND GINSENOSIDE RG5 AND THEIR PHARMACEUTICAL USES INCLUDING ANTI-TUMOR EFFECTSFebruary 2023December 2025Abandon3401NoNo
18018473A COMPOSITION COMPRISING AN EXTRACT OF ALDER TREE OR THE ISOLATED COMPOUNDS THEREFROM FOR TREATING AND PREVENTING SKELETON MUSCLE-RELATED DISORDER AND THE USE THEREOFJanuary 2023December 2025Abandon3501NoNo
18005853USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIESJanuary 2023March 2026Allow3810NoNo
18096508MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSJanuary 2023August 2023Allow710YesNo
18150741TABLETS HAVING DISCONTINUOUS COATED REGIONSJanuary 2023November 2025Allow3510NoNo
18013919DRUG-CLAY MINERAL COMPLEX CONTAINING PHOSPHOLIPID AND ORAL ADMINISTRATION COMPOSITION INCLUDING SAMEDecember 2022January 2026Allow3611NoNo
18083477Liver VitalityDecember 2022March 2026Abandon3911NoNo
18063281SAUVIGNON BLANC GRAPE SEED PRODUCTS FOR NONALCOHOLIC FATTY LIVER DISEASEDecember 2022March 2026Abandon3910NoNo
18075980MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSDecember 2022July 2023Allow810YesNo
18061848METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUGDecember 2022January 2024Allow1310NoNo
18053557Rucaparib particles and uses thereofNovember 2022March 2023Allow401NoNo
17922884COMPOSITION TO BE USED FOR STRENGTHENING THE IMMUNE SYSTEM IN HUMAN AND ANIMAL TO ACQUIRE PAN-IMMUNITYNovember 2022November 2025Abandon3701NoNo
17966538MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSOctober 2022September 2025Allow3510YesNo
18045075ANTI-VIRAL CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOFOctober 2022June 2025Allow3221NoNo
17959746BIOERODIBLE DRUG DELIVERY DEVICESOctober 2022September 2025Allow3520YesNo
17912625TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES MELLITUS 10 TYPE I AND TYPE II AND THYROID DISEASESSeptember 2022February 2026Abandon4101NoNo
17946243EXTENDED RELEASE, ABUSE DETERRENT DOSAGE FORMSSeptember 2022September 2024Allow2410NoNo
17908079USE OF COMPOUNDS IN THE TREATMENT OF FUNGAL INFECTIONSAugust 2022November 2025Allow3910YesNo
17821786Bis-Choline Tetrathiomolybdate for Treating Wilson DiseaseAugust 2022October 2024Allow2610YesNo
17883902EXTENDED RELEASE PHARMACEUTICAL FORMULATIONAugust 2022August 2025Allow3611YesNo
17851451EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENTJune 2022March 2025Allow3201YesNo
17851590EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENTJune 2022March 2025Allow3220YesNo
17849328OPHTHALMIC COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGE TO AN EYE LENSJune 2022May 2025Allow3511YesNo
17839940PATHOGEN DESTRUCTION SYSTEM AND METHOD USING MAGNETIC MARKERSJune 2022March 2026Allow4520YesYes
17838636METHOD OF TREATING PAIN UTILIZING CONTROLLED RELEASE OXYMORPHONE PHARMACEUTICAL COMPOSITIONS AND INSTRUCTION ON DOSING FOR RENAL IMPAIRMENTJune 2022March 2026Abandon4520NoYes
17834839PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOFJune 2022August 2024Allow2610NoNo
17804312CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOFMay 2022September 2024Allow2810NoNo
17775889INFANT FORMULA WITH SPECIAL LIPID ARCHITECTURE FOR IMPROVING POSTNATAL GROWTH OF INFANTS BORN BY CAESAREAN SECTIONMay 2022March 2023Allow1010NoNo
17729162PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291April 2022December 2024Abandon3110NoNo
17722158IMMEDIATE-RELEASE TABLETS CONTAINING A DRUG AND PROCESSES FOR FORMING THE TABLETSApril 2022August 2025Abandon4011NoNo
17697084BIOERODIBLE DRUG DELIVERY DEVICESMarch 2022February 2025Allow3520NoNo
17691552Compositions and Methods for Attracting Mosquitoes and Repelling Sand FliesMarch 2022March 2025Abandon3601NoNo
17689255MODIFIED RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAMEMarch 2022November 2025Allow4421NoNo
17687373ORALLY DISINTEGRATING, SUBLINGUAL AND BUCCAL FORMULATIONSMarch 2022December 2024Abandon3310NoNo
17674042METHOD OF PREPARING AN ANIMAL TREAT COMPOSITIONFebruary 2022September 2024Allow3110YesNo
17673063METHODS FOR MAKING MULTILAYERED VESICLESFebruary 2022September 2025Allow4330NoNo
17665372DEVICE FOR CUTTING AN ANIMAL TREAT COMPOSITIONFebruary 2022September 2024Allow3210NoNo
17665392Systems and Methods for Troche ProductionFebruary 2022May 2025Allow3921NoNo
17576687METHODS OF TREATMENT USING SUSTAINED RELEASE SOTALOL FORMULATIONSJanuary 2022July 2025Abandon4220NoNo
17569047ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONSJanuary 2022October 2024Allow3310NoNo
17564812SCINTILLATOR NANOCRYSTAL-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USEDecember 2021August 2024Allow3110YesNo
17530096MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSNovember 2021March 2024Allow2820YesYes
17528543BIO-ADHESIVE DISSOLVING COMPOUNDS AND DEVICENovember 2021July 2025Allow4411YesNo
17452996LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOFOctober 2021August 2024Allow3310NoNo
17502701Stable Therapeutic FormulationsOctober 2021February 2026Abandon5231NoNo
17497381MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSOctober 2021December 2022Allow1420YesNo
17497393MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSOctober 2021December 2022Allow1420YesNo
17497366MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICSOctober 2021September 2022Allow1121YesNo
17494180NITRIC OXIDE TOPICAL APPLICATION APPARATUS AND METHODSOctober 2021November 2025Abandon4910NoNo
17485447CANNABIS CALIBRATION SYSTEM-DERIVED PRODUCTS AND METHOD OF MAKING SAMESeptember 2021February 2026Abandon5210NoNo
17485446METHOD FOR INCREASING THC/CBD CONTENT IN A CANNABIS PRODUCTSeptember 2021February 2026Abandon5211NoNo
17442239EXTENDED RELEASE PHARMACEUTICAL FORMULATIONSeptember 2021June 2024Allow3311YesNo
17478117PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291September 2021December 2024Abandon3910NoNo
17475528SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENTSeptember 2021August 2024Allow3521NoNo
17467655Taxane Particles and Their UseSeptember 2021February 2025Abandon4120NoNo
17460476METHOD FOR TREATMENT OF DEPRESSION WITH ORAL DOSAGE FORMS OF KETAMINEAugust 2021March 2025Allow4230YesNo
17398413ANTI-ODOR COMPOSITIONS, STRUCTURES HAVING ANTI-ODOR CHARACTERISTICS, METHODS OF MAKING THE ANTI-ODOR COMPOSITIONS AND THE STRUCTURESAugust 2021May 2025Allow4540YesNo
17353149ORALLY DISINTEGRATING, SUBLINGUAL AND BUCCAL FORMULATIONSJune 2021February 2022Allow810YesNo
17304309METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUGJune 2021December 2023Allow3010NoNo
17347469Solid Oral Sulfate Salt Formulations For Cleansing A Colon And Methods Of Using SameJune 2021February 2022Allow810NoNo
17340973Solid Oral Sulfate Salt Formulations For Cleaning A Colon And Methods of Using SameJune 2021August 2022Allow1420NoNo
17335235Submucosal Lifting Compositions and Methods of SameJune 2021March 2024Allow3341YesNo
17298408ADHESIVE PADMay 2021July 2025Allow4930YesNo
17328633MICROFLUIDIC EXTRUSIONMay 2021February 2022Allow810NoNo
17328854Microfluidic ExtrusionMay 2021March 2022Allow1030YesNo
17314272METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTSMay 2021December 2024Allow4320NoNo
17291073MEDICAMENTS CONTAINING RIBOFLAVIN EXHIBITING IMPROVED FLOWABILITYMay 2021January 2024Allow3210YesNo
17244158NITRIC OXIDE TOPICAL APPLICATION APPARATUS AND METHODSApril 2021January 2024Allow3310NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SASAN, ARADHANA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
21
Examiner Affirmed
13
(61.9%)
Examiner Reversed
8
(38.1%)
Reversal Percentile
59.7%
Higher than average

What This Means

With a 38.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
143
Allowed After Appeal Filing
34
(23.8%)
Not Allowed After Appeal Filing
109
(76.2%)
Filing Benefit Percentile
32.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SASAN, ARADHANA - Prosecution Strategy Guide

Executive Summary

Examiner SASAN, ARADHANA works in Art Unit 1615 and has examined 1,140 patent applications in our dataset. With an allowance rate of 61.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner SASAN, ARADHANA's allowance rate of 61.8% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SASAN, ARADHANA receive 2.17 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SASAN, ARADHANA is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +23.3% benefit to allowance rate for applications examined by SASAN, ARADHANA. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.1% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 73.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 79.2% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 63.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.